Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors.
about
The β-Lactams Strike Back: Ceftazidime-AvibactamNew β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Investigational antimicrobial agents of 2013.Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.The intrinsic resistome of bacterial pathogens.Combating multidrug-resistant Gram-negative bacterial infections.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal DiseaseWhat we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic modelImipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Relebactam is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores the Susceptibility of Imipenem Against KPC-Producing Enterobacteriaceae.Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.
P2860
Q26796425-C7DA82D1-84B4-4BD0-9EC4-5BF5B84E7551Q33622976-6A2E73B6-7AFE-4D50-8D7F-36AD24CA3B75Q34375204-154765CE-7278-4D8E-9E5C-62B6EC97BCE9Q37308807-53D2D1D3-130B-4340-A83C-7F2EF4679375Q38103861-5E6091DA-FF5E-4F3D-ABC3-1492C6901A8CQ38161570-DCB33FC9-361D-496B-8133-ED16B5B6BA79Q38797485-4212CF0E-0C30-40A2-AB3B-E07944EEEA23Q39001350-5E2C153F-6E08-4CCB-A905-AC8ADC7305F9Q39066154-D22D0DC8-6AD2-4C81-89A9-24F89E22C411Q39120027-78D75D70-AA40-4DFA-BD74-D4B52A2D47F1Q39133476-4692196E-EC15-45D3-8C47-A1F268F097ADQ40375783-A5FDB37F-7C5F-454C-BAB7-EA60A03D4065Q41077573-69D8791C-2635-444F-8443-DF91237C7377Q46243175-9BAE984D-C0D7-41F0-A748-7C219699946FQ52334116-93CBA716-8C92-436C-8120-1DB0E856A565Q52366733-C657668B-873B-4ED4-B460-CD7A13FD2586
P2860
Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Novel modeling framework to gu ...... es for β-lactamase inhibitors.
@ast
Novel modeling framework to gu ...... es for β-lactamase inhibitors.
@en
type
label
Novel modeling framework to gu ...... es for β-lactamase inhibitors.
@ast
Novel modeling framework to gu ...... es for β-lactamase inhibitors.
@en
prefLabel
Novel modeling framework to gu ...... es for β-lactamase inhibitors.
@ast
Novel modeling framework to gu ...... es for β-lactamase inhibitors.
@en
P2093
P2860
P356
P1476
Novel modeling framework to gu ...... es for β-lactamase inhibitors.
@en
P2093
Elizabeth B Hirsch
Kai-Tai Chang
Kimberly R Ledesma
Michael Nikolaou
Pratik Bhagunde
Vincent H Tam
P2860
P304
P356
10.1128/AAC.06113-11
P407
P577
2012-02-13T00:00:00Z